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Background and Purpose 
Calcium/calmodulin-GHSHQGHQWSURWHLQNLQDVH,,į&D0.,,įLVDQLPSRUWDQWUHJXODWRURIFDUGLDF
contractile function and dysfunction and may be an unwanted secondary target for anti-cancer drugs 
such as sunitinib and imatinib that have been reported to alter cardiac performance.  This study 
aimed to determine whether anti-cancer kinase inhibitors may affect CaMKII activity and 
expression when administered in vivo. 
Experimental Approach  
A guinea pig model was used to assess cardiovascular haemodynamics in response to acute and 
chronic sunitinib treatment, and chronic imatinib treatment. The effects were compared with known 
positive and negative inotropes isoprenaline and verapamil.  Parallel studies from the same animals 
assessed CaMKIIį expression and CaMKII activity following drug treatments.  Acute 
administration of sunitinib decreased left ventricular (LV) dP/dtmax. Acute administration of 
isoprenaline increased LVdP/dtmax in a dose-dependent manner while LVdP/dtmax was decreased by 
verapamil.  CaMKII activity was decreased by acute administration of sunitinib and was increased 
by acute administration of isoprenaline and decreased by acute administration of verapamil.  
&D0.,,įH[SUHVVLRQfollowing all acute treatments remained unchanged.  Chronic imatinib and 
VXQLWLQLEWUHDWPHQWVGLGQRWDOWHUIUDFWLRQDOVKRUWHQLQJKRZHYHUERWK&D0.,,įH[SUHVVLRQDQG
CaMKII activity were significantly increased.  Chronic administration of isoprenaline and 
verapamil decreased left ventricular fractional shortening with parallel increases in &D0.,,į
expression and CaMKII activity.   
Conclusions and Implications 
Using an integrated approach, this study indicates increased &D0.,,įH[SUHVVLRQDQG&D0.,,
activity occur following chronic sunitinib and imatinib treatment.  Given the association of these 
compounds with cardiac dysfunction, increased CaMKII expression could be an early indication of 
cellular cardiotoxicity marking potential progression of cardiac contractile dysfunction. 
 
Abbreviations:  AIP, autocamtide inhibitory peptide; CaMKII, calcium/calmodulin dependent 
protein kinase II; DBP, diastolic blood pressure; FS, fractional shortening; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; LV, left ventricular; LVdP/dtmax, maximum rate of rise of left 
ventricular pressure; LVDD, left ventricular diastolic diameter; LVEDP, left ventricular end 
diastolic pressure; LVP, left ventricular pressure; LVSD, left ventricular systolic diameter; ROS, 
reactive oxygen species; RyR, ryanodine receptor; SBP, systolic blood pressure; SR, sarcoplasmic 
reticulum. 
 
  
Introduction 
&DUGLRWR[LFLW\LVDFRPPRQVLGHHIIHFWRIPDQ\µVXFFHVVIXO¶DQWL-cancer agents (Curigliano et al., 
2010).  Although improvements in regression of cancer growth and metastasis have been observed 
with these agents, a range of cardiac toxicities can occur.  These include ECG changes and left 
ventricular (LV) contractile dysfunction, leading in some cases to congestive heart failure.   
 
One class of anti-cancer agents with proven cardiotoxic effects are the kinase inhibitors (Cheng and 
Force, 2010)  Kinases, in particular tyrosine kinases, play an important role in tumour angiogenesis 
and cell proliferation.  Inhibition of these enzymes slows tumour progression leading to shrinkage 
of the tumour mass.  Unfortunately, and in spite of their potential for targeted effects, some 
members of this family of inhibitors exhibit marked cardiotoxicity.  Imatinib was the first of these 
kinase inhibitors to gain FDA approval and cardiotoxicity was not predicted by preclinical studies.  
Following approval, however, it was reported that development of heart failure was associated with 
imatinib treatment in some patients (Kerkela et al., 2006). 
 
Unlike imatinib, sunitinib is a kinase inhibitor that is clearly associated with clinical cardiotoxicity.  
Preclinical evaluations have shown sunitinib to cause LV hypertrophy and hypertension (Maayah et 
al., 2014; Blasi et al., 2012).  Clinically, prolongation of the QT interval has been observed (Bello et 
al., 2009) and a retrospective study found that 15% of sunitinib-treated patients developed 
symptomatic grade 3/4 LV dysfunction (Telli et al., 2008) whilst in another study 8% of patients 
developed heart failure following 33.6 weeks median treatment duration (Chu et al., 2007). 
 
Sunitinib has multiple targets including vascular endothelial growth factor receptors, platelet 
derived growth factor receptors, FMS-like tyrosine kinase 3 and c-kit.  A key issue with the limited 
selectivity of sunitinib is the likelihood RIµRII-target WR[LFLW\¶ caused by the action of sunitinib on 
proteins other than those that are recognised targets (Cheng and Force, 2010).  One example 
recently identified was AMP activated protein kinase.  This kinase has an essential role in metabolic 
homeostasis in the heart and, as such, alterations in its activity following sunitinib treatment have 
been shown to cause compromised cardiac myocyte function (Kerkela et al., 2009).  There could 
potentially be a large number of µRII-WDUJHW¶HIIHFWV of sunitinib (and indeed other members of the 
kinase inhibitor family) (Ghoreschi  et al., 2009).  However, these additional targets and the 
contribution they make to the cardiotoxic properties of these small molecule inhibitors have yet to 
be fully assessed. 
 
One kinase that plays a crucial role in cardiac function is calcium/calmodulin dependent protein 
kinase II (CaMKII).  CaMKII exists as four dLIIHUHQWLVRIRUPVĮȕȖDQGį, with the įisoform 
being the predominant isoform expressed in the heart.  As well as acting as a key modulator of 
cardiac calcium handling and contractility, CaMKIIį has also been suggested to regulate the cardiac 
inflammatory response, transcriptional events and non-contractile cardiac cell proliferation (Currie 
et al., 2011; Martin et al., 2014).  Importantly, CaMKIIį is recognised not only as a critical 
modulator of normal cardiac function, but is also established as a fundamental molecular switch 
that, when excessively expressed and activated, can trigger pathophysiological events leading 
ultimately to heart failure (Anderson et al., 2007).  Pathophysiological consequences of increased 
CaMKIIį activity include a range of effects on cardiac ion channels influencing depolarisation, 
cardiac excitability and repolarisation of cardiac myocytes (Anderson, 2007).  Dysfunctional 
sarcoplasmic reticulum (SR) Ca2+ handling is evident following CaMKIIį-mediated 
hyperphosphorylation of the SR Ca2+ release channel, the ryanodine receptor (RyR), which leads to 
increased diastolic Ca2+ release and a propensity for cardiac arrhythmias (Wehrens et al., 2004). As 
well as coordinating contractile dysfunction, CaMKIIį activation can also increase the activity of 
pro-inflammatory mediators and the development of fibrosis.  As such, it links a number of both 
acute and chronic pathological events in the progression of heart disease and has been referred to as 
a prime candidate for therapeutic targeting (Currie et al., 2011; Anderson, 2007). 
 
The possibility that cardiotoxic effects of kinase inhibitors may be mediated via CaMKII has not 
previously been investigated in vivo.  This is surprising given the overwhelming recognition that 
elevated CaMKIIį is central to cardiac pathophysiology.  Previously, we have optimised conditions 
for studying the acute effects of drugs on indices of cardiac contractility and haemodynamics in an 
anaesthetised guinea pig model (Mooney et al., 2012).  In this study we have also developed the 
guinea pig model to allow assessment of more prolonged dosing of drugs on cardiovascular 
function.  Using these techniques, we have compared the effects of sunitinib and imatinib with 
recognised positive and negative inotropes.  Applying an integrated approach we have also assessed 
in parallel, the effects of these drugs on CaMKIIį expression and CaMKII activity in LV tissue 
taken from the same animals.   
 
Methods 
Animals and anaesthesia 
All animal experiments were performed in accordance with the UK Animals (Scientific Procedures) 
Act 1986, approved by institutional ethical review committees and conducted under the authority of 
project licences held at the University of Strathclyde or at AstraZeneca.  A total of fifty male 
Dunkin Hartley guinea pigs (440 ± 650 g) were purchased from Harlan (Bicester, UK).  In acute 
experiments animals were anaesthetised with fentanyl (50 µg kg-1 s.c.) followed by sodium 
pentobarbital (50-60 mg kg-1 i.p.).  Throughout haemodynamic assessments anaesthesia was 
maintained by a continuous i.v. infusion of sodium pentobarbital (12 mg ml-1) at 6 mg kg-1 hr-1 
using an infusion pump.  In chronic experiments animals were anaesthetised using a combination of 
Hypnorm® and Hypnovel® (6 ml kg-1 i.p. of a solution containing 1 part Hypnorm (fentanyl citrate 
0.315 mg mlí1 DQGÀXDQLVRQHPJPOí1); 1 part Hypnovel (midazolam HCl 5 mg mlí1) and 2 
parts water made up freshly each day) for echocardiography assessments, and maintained for 
haemodynamic assessment with sodium pentobarbital as described above.  A different anaesthetic 
regimen was used for the chronic experiments taking into account the requirement for recovery 
following initial echocardiography assessment. Although Hypnorm® and Hypnovel® can cause a 
decline in heart rate (Mooney et al., 2012), this is not observed until after 15 minutes and at higher 
concentrations than that used here.  Full details of animal housing conditions, diet, surgical 
preparation and all equipment have been published previously (Mooney et al., 2012). 
 
Haemodynamic assessment 
Immediately after induction of an adequate level of anaesthesia, as determined by the absence of 
corneal and/or pedal withdrawal reflexes, the trachea was cannulated and animals were artificially 
ventilated with room air.  Oxygen saturation and expired CO2 were measured continuously using a 
pulse oximeter/capnograph (0HGDLU/LIHVHQVH). If necessary, during the preparation and 
stabilisation phases, the stroke volume of the pump was adjusted to keep the end-tidal CO2 value 
between 35 and 45mmHg and oxygen saturation above 95%. Blood gas values were kept within a 
set range: PO2 >70 and <110mmHg, PCO2 >25 and <45mmHg.  ECG was recorded via 
subcutaneous limb leads (for monitoring only), arterial blood pressure (BP) via a fluid-filled 
cannula in the right carotid artery, and left ventricular pressure (LVP) via a 2F or 3F Millar Mikro-
tip® catheter pressure transducer (Millar Inc, TX, USA) or a 1.6F Scisense pressure catheter 
(SciSense Inc, London ON Canada) advanced through the left carotid artery so that its tip lay in the 
lumen of the LV.  Drugs or vehicle were delivered via a jugular venous cannula.  Body temperature 
was monitored throughout experiments via a rectal thermometer and maintained ~37ºC using a 
heating lamp.  All data were recorded continuously and processed using Ponemah P3 Plus software. 
 
Acute experimental protocol 
Twenty guinea pigs weighing 460 ± 650 g were used to assess acute drug effects.  After completing 
the full surgical preparation a 20 min stabilisation period was allowed.  Guinea pigs received either 
sunitinib (0.3, 1.0 aQGȝPRONJ-1 min-1)(1.8, 6 and 18 mg kg-1), isoprenaline (0.1, 0.3, 1.0 nmol kg-
1
 min-1) (0.3, 0.9 and 3 Pg kg-1), verapamil (14, 42 and 140 nmol kg-1 min-1)(95, 286, 955 Pg kg-1) 
or YHKLFOHHTXDOYROXPHVRIQRUPDOVDOLQHȝONJ-1 min-1) as continuous i.v. infusions 
with each dose being infused for 15 min.  Following infusion of the final dose animals were 
euthanised by removal of the heart. 
 
Chronic experimental protocol 
Thirty guinea pigs weighing 440 ± 560 g at the start of procedures were used to assess chronic drug 
effects.  On day 0, guinea pigs were anaesthetised and transthoracic echocardiography was 
performed using a 13-MHz linear array transducer and HDI® 3000 ultrasound system (ASL 
Ultrasound).  M-mode short axis images of the LV were obtained and LV diastolic and systolic 
diameters (LVDD and LVSD, respectively) were measured to determine % fractional shortening 
(FS).  Immediately following this, an osmotic minipump (Alzet® Model 2ML1; Charles River) was 
implanted subcutaneously at the neck to deliver sunitinib (40 µmol kg-1 day-1)(16mg kg-1 day-1), 
imatinib (170 µmol kg-1 day-1)(84mg kg-1 day-1), isoprenaline (1.5 µmol kg-1 day-1)(317 Pg kg-1 day-
1), verapamil (20 µmol kg-1 day-1)(9.1 mg kg-1 day-1), , or vehicle (0.1% acidified saline) over 6 
days.  All drugs were dissolved in 0.1% ascorbic acid in 0.9% w/v NaCl except imatinib which was 
dissolved in 0.9% w/v NaCl. On day 6, guinea pigs were re-anaesthetised and echocardiography 
was repeated.  Haemodynamic assessment was then performed as described above.  At the end of 
this animals were euthanised by removal of the heart. 
 
Tissue preparation 
The heart was weighed following removal and a transverse section taken through the right and left 
ventricle and fixed in 10% formalin for subsequently histological analysis.  The remaining LV was 
cut into chunks, snap frozen in liquid nitrogen and stored at -80°C.  As required, LV tissue was 
homogenised in buffer containing 20 mM Tris-HCl, pH7.2, 1 mM DTT, phosphatase inhibitors (0.5 
mM calyculin A, 4 mM Na orthovanadate) and protease inhibitors (cocktail set V, EDTA free; 
Calbiochem).  The total protein content was determined using the Coomassie Plus protein assay 
(Pierce). 
 
Immunoblotting 
LV homogenates were subjected to SDS-PAGE using the NuPAGE system (Invitrogen); 10% Bis-
Tris gels for CaMKII and 3-8% Tris-Acetate gels for RyR.  Antibodies were as follows: Custom 
made polyclonal antibody (rabbit IgG) DJDLQVWWKH&WHUPLQXVRI&D0.,,į Eurogentec), 
rabbit polyclonal anti-phosphoRyR (Ser-2815) IgG (1:2000, Badrilla), mouse monoclonal anti-
GAPDH IgG (1:80,000, Abcam).  Either goat anti-mouse or anti-rabbit-horseradish peroxidise 
conjugate (Sigma and GE Healthcare) were used as secondaries.  Films were quantified using a 
GS800 calibrated densitometer and Quantity One software (Bio-Rad Laboratories Ltd.).  GAPDH 
was used for intra-gel normalisation.  CaMKII:GAPDH and pSer2815-RyR:GAPDH ratios were 
calculated for each sample and these were then normalised to an untreated sample (aliquots from 
the same preparation) included in every gel to allow inter-gel normalisation.  The latter 
normalisation was performed due to the number of samples, which had to be run across several 
different gels. 
 
CaMKII activity assay 
CaMKII activity was determined in triplicate in LV tissue homogenates by measuring the 
LQFRUSRUDWLRQRIȖ-32P into a CaMKII peptide substrate, autocamtide-2 as described previously 
(Anthony et al., 2007).  Controls included homogenates measured in the absence of Ca2+ (5mM 
EGTA), absence of substrate, and inclusion of autocamtide inhibitory peptide (AIP), a recognised 
CaMKII inhibitor.  Individual activity values were converted to pmol of phosphate incorporated 
min-1 ȝJSURWHLQ-1 and normalised to the calculated activity of an untreated sample included in every 
assay, in line with immunoblotting analyses. 
 
Plasma drug and cardiac troponin I concentrations 
In acute and chronic experiments, blood samples were collected in 1.3 ml lithium heparin tubes 
from the open chest at the end of the haemodynamic assessment and immediately after removal of 
the heart.  Plasma was prepared by centrifugation (AccuSpin MicroR centrifuge, Fisher Scientific) 
at 3000 rpm for 10 min, aliquoted and stored at -80°C until analysis.  Total plasma drug 
concentrations were determined by HPLC-MS/MS.  On day 6 of the chronic dosing study blood 
samples were also collected for determination of plasma cardiac troponin I using the ADVIA 
Centaur® CP Immunosystem cTnI-UltraTM assay (Medical Siemens). 
 
Drugs 
Fentanyl, Hypnorm® and Hypnovel® were obtained from veterinary wholesalers through the 
Biological Procedures Unit at the University of Strathclyde.  Sodium pentobarbital, isoprenaline 
HCl and verapamil were obtained from Sigma-Aldrich.  Sunitinib and imatinib were purchased 
from Sequoia Research Products Ltd.  All drugs were dissolved in 0.9% w/v NaCl for acute 
administration or 0.1% acidified saline for chronic administration. 
 
Data Analysis 
Results are presented as mean ± SEM.  In acute experiments, haemodynamic data were averaged 
over 5 s at 1, 2, 3, 4, 5, 10 and 15 min after the start of each infusion and drug effects were 
determined by Kruskal-Wallis tests.  At the end of the chronic dosing experiments, haemodynamics 
were averaged over 15 min and drug effects were assessed by comparison to the vehicle group 
using a one way ANOVA IROORZHGE\'XQQHWW¶VWHVWHaemodynamic effects are presented as a % 
change from baseline to allow clear comparison across drug groups. For echocardiography 
H[SHULPHQWVSUHGD\DQGSRVWGD\WUHDWPHQWPHDVXUHPHQWVZHUHFRPSDUHGXVLQJ6WXGHQW¶V
paired t-test.  Kruskal-:DOOLVWHVWVZHUHXVHGIRUFRPSDULVRQVRI&D0.,,į expression, CaMKII 
activity, pSer2815-RyR expression and cardiac troponin I concentrations among groups because 
some of the data were not distributed normally. 
 
Results 
Acute sunitinib treatment caused a decrease in LVdP/dtmax that was accompanied by a fall in heart 
rate and blood pressure 
Sunitinib decreased LVdP/dtmax in a dose-dependent manner with significant changes appearing at 
the beginning of infusion of the second dose (Figure 1).  As expected, the negative inotrope 
verapamil also reduced LVdP/dtmax whereas the positive inotrope isoprenaline caused rapid dose-
dependent increases (Figure 1).  The changes in heart rate induced by these drugs were similar to 
their effects on LVdP/dtmax; sunitinib and verapamil decreased heart rate and isoprenaline caused an 
increase (Figure 2A).  However, although sunitinib and verapamil caused significant, dose-
dependent reductions in systolic and diastolic arterial BP, isoprenaline did not alter either parameter 
significantly (Figure 2B and C).  Acute treatment with vehicle had no significant effects on any of 
the parameters. 
 
CaMKII activity was significantly reduced following acute sunitinib treatment 
Quantitative immunoblotting for CaMKIIįrevealed no differences in expression of the protein in 
LV homogenates across all acute treatment groups (Figure 3A).  The same homogenates were then 
assessed for CaMKII activity.  When compared with vehicle, sunitinib and verapamil treatment 
significantly decreased CAMKII activity and, as expected, acute isoprenaline administration 
increased CAMKII activity. (Figure 3B). 
 
To test the sensitivity of the CaMKII activity assay, LV homogenate was assessed alone, in the 
presence of the CaMKII inhibitor AIP (3 µM and 10 µM), in the absence of CaMKII peptide 
substrate and in the presence of 5 mM EGTA to remove extracellular Ca2+.  All of these treatments 
resulted in inhibition of CaMKII basal activity as expected, confirming the sensitivity of the assay 
(Figure 3C). 
 
Chronic administration of either sunitinib or imatinib had no significant effects on LVdP/dtmax, 
heart rate, blood pressure or fractional shortening 
Echocardiography was used to assess left ventricular diameter and fractional shortening (FS) before 
and after chronic drug administration.  A short-axis view of the guinea pig heart is shown in Fig. 4A 
along with a corresponding M-mode recording.  LV diameters and FS remained unchanged 
following chronic administration with sunitinib and imatinib. LVDD was increased by 23% and 
LVSD by 89% in the isoprenaline group.  LVSD was increased by 34% following verapamil 
administration.  FS was decreased significantly in both the isoprenaline and verapamil groups by 
28% and 24%, respectively (Figure 4B). 
 
Sunitinib and imatinib also had no effect on LVdP/dtmax during the final haemodynamic assessment 
whereas this index of cardiac contractility was decreased significantly in the verapamil group 
(Table 1).  None of the drugs caused significant changes in heart rate and the only drug which 
affected BP was verapamil which reduced both systolic and diastolic arterial BP significantly 
(Table 1). 
 
There were no changes in heart:body weight ratio (Table 1) and no cardiac histopathological 
changes following any of the chronic drug treatments. 
  
CaMKIIį expression and CaMKII activity were both significantly increased by chronic sunitinib 
and imatinib administration 
Expression of &D0.,,įprotein increased in response to chronic treatment in all drug groups 
compared to the vehicle group (Figure 5).  Verapamil caused the greatest increase in expression 
(96%), followed by imatinib (62%), sunitinib (23%) and isoprenaline (22%).  Parallel experiments 
were performed to measure changes in CaMKII activity following chronic drug treatment.  The 
greatest increase was in the sunitinib group (110%), followed by isoprenaline (78%), verapamil 
(70%) and imatinib (50%) (Figure 6A). 
 
CaMKII-dependent phosphorylation of RyR was increased following chronic administration of 
sunitinib and imatinib 
In order to confirm the increase in activity measured using the CaMKII activity assay, quantitative 
immunoblotting of the CaMKII-selective phosphorylation site on RyR, serine 2815 (pSer2815-
RyR), was used as a second assessment of CaMKII activity.  All chronic treatments resulted in an 
increase in pSer2815-RyR expression when compared with vehicle treatment (Figure 6B).  Again 
the largest increase was with sunitinib treatment (123%), but this time it was followed by imatinib 
(61%) then isoprenaline and verapamil which were similarly effective causing increases in 
pSer2815-RyR expression of 16 and 12%, respectively. 
 
Plasma drug and cardiac troponin I concentrations 
In the acute phase studies, total plasma drug concentrations achieved at the end of the dosing period 
were: sunitinib 25.4 ± 8.3 µM and verapamil 7.8 ± 2.9 µM.  In the chronic dosing groups, total 
plasma drug concentrations, respectively, were: sunitinib 0.01 ± 0.002 µM (clinically relevant 
concentration is 0.06PM) ; imatinib 1.36 ± 0.38 µM (clinically relevant concentration is 2PM); 
verapamil 0.16 ± 0.02 µM.  Plasma drug concentrations for isoprenaline could not be determined as 
a suitable method could not be established. 
 
Plasma cardiac troponin I concentrations for each chronic treatment group were: sunitinib 3.56 ± 
1.13 ng ml-1; imatinib 2.24 ± 0.54 ng ml-1verapamil 9.16 ± 4.76* ng ml-1;isoprenaline 1.80 ± 0.37 
ng ml-1; vehicle 1.42 ± 0.47 ng ml-1 (* indicates P<0.05 compared to vehicle group, Kruskal-Wallis 
test). 
 
Discussion 
The central finding of this study is that chronic treatment with anti-cancer kinase inhibitors, 
VXQLWLQLEDQGLPDWLQLELQFUHDVHGFDUGLDF&D0.,,įH[SUHVVLRQDQG&D0.,,DFWLYLW\LQJXLQHDSLJV
in the absence of any overt cardiac dysfunction.   Since both agents have been associated with 
cardiotoxicity in the clinic these changes could reflect early adaptations by the heart to these anti-
cancer kinase inhibitors which could precede the onset of contractile dysfunction.  We have 
specifically examined the anti-cancer agents sunitinib and imatinib; however, the potential role of 
CaMKII in modulating cardiotoxic effects of other anti-cancer therapies should not be overlooked. 
 
Acute drug effects 
Acute treatment with sunitinib (3 x 15 min infusions) caused significant haemodynamic effects in 
anaesthetised guinea pigs.  With cumulative infusions there was a significant decrease in 
LVdP/dtmax as well as significant decreases in both systolic and diastolic BP.  Decreases in blood 
pressure of such a magnitude would be expected to result in a reflex tachycardia based on the 
known baroreflex sensitivity of this model (Mooney et al., 2012); however, sunitinib caused a dose-
dependent decrease in heart rate.  In the acute studies a large dose range was explored, from an 
initial dose, expected to yield clinically relevant plasma concentrations, to higher doses that yielded 
concentrations well in excess of efficacious concentrations.    Since sunitinib is a relatively non-
selective kinase inhibitor, the cardiovascular effects, observed at supratherapeutic exposures, are 
likely due to actions at other secondary molecular targets (eg tyrosine kinases or GPCRs)(Sutent 
FDA Pharm Review). Previous experiments with sunitinib in rats have shown that it causes a dose-
dependent hypertension, possibly due to its inhibition of VEGF signalling; however, this effect is 
only apparent after repeated dosing (Isobe et al., 2014, Blasi et al., 2012). 
 
Overall, these results suggest that acute administration of sunitinib, at high doses, causes a negative 
chronotropy, and may also reduce inotropy. A similar haemodynamic profile was observed with the 
calcium channel antagonist verapamil in agreement with previous studies in this model (Marks et 
al., 2012).  In contrast, isoprenaline increased LVdP/dtmax and heart rate, in line with its positive 
inotropic and chronotropic actions, and had no effect on systolic or diastolic arterial BP.    
 
It is well known that LVdP/dtmax can be influenced by changes in cardiac loading and heart rate 
(Wallace et al., 1963; Markert et al., 2012).  Previous studies in guinea pigs have shown LVdP/dtmax 
to be positively influenced when mean arterial BP is >80 ± 8 mmHg and negatively influenced 
when mean arterial BP is <39 ± 3 mmHg (Mooney, 2012).  In addition, LVdP/dtmax increased with 
increases in heart rate to peak values of 220-249 beats min-1, after which LVdP/dtmax decreased with 
further increases in heart rate (Mooney, 2012).  In the present study, during the final infusions of 
both sunitinib and verapamil , mean arterial BP and heart rate decreased below 39 mmHg and 
220bpm, respectively.  In isoprenaline experiments mean arterial BP was not significantly altered 
and heart rate was maintained above 249 beats min-1.  Therefore, it must be borne in mind that the 
changes in LVdP/dtmax induced with sunitinib and verapamil administration may also be a 
consequence of the concurrent changes in heart rate and/or arterial BP. 
 
Interestingly, when CaMKII was assessed from acute drug-treated hearts, although there was no 
change in Ca0.,,įSURWHLQH[SUHVVLRQZLWKDQ\RIWKHGUXJWUHDWPHQWVZKLFKLVXQVXUSULVLQJRYHU
such a short time scale), changes in activity were observed.  Specifically, sunitinib caused a 
significant decrease in CaMKII activity as did verapamil.  Acute administration of isoprenaline 
caused CaMKII activity to increase.  This is in agreement with previous studies in rats and mice 
(Yoo et al., 2009; Grimm & Brown 2010) but is the first time this relationship has been 
demonstrated in guinea pigs in vivo.  Previous work has suggested that a significant element of E-
adrenergic signalling is mediated via CaMKII and that this contributes to the pathophysiology 
observed in heart failure (Grimm & Brown 2010).  It may also be the case that drugs already used in 
the treatment of various cardiomyopathies (such as E-blockers) can target CaMKII albeit non-
specifically (Currie et al., 2011; Grimm & Brown 2010). Given the pivotal role that CaMKII plays 
in cardiac function and dysfunction and the potential it has as a target for mediating therapeutic 
effects, it seems likely that it could also be an unwanted secondary target for drugs exhibiting 
adverse cardiac side effects.  This is of interest when examining acute sunitinib treatment where 
there is evidence for significantly altered CaMKII activity.     
 
Chronic drug effects 
Chronic drug administration via mini-pump delivery over 6 days used the same standard inotropes 
and included imatinib as well as sunitinib.  Ideally, it would have been beneficial to include chronic 
administration of a CaMKII selective modulator. We had originally planned to include AIP; 
however, the costs involved in administering this peptide over 6 days in the guinea pig were 
prohibitive. Chronic selective inhibition of CaMKII has proved feasible in mice where studies have 
administered the CaMKII inhibitor KN-93 or used genetic models where the autoinhibitory domain 
of the kinase is targeted (Zhang et al., 2005; Kaurstad et al., 2012). These studies provide support to 
the capability of chronic and selective targeting of CaMKII.  
 
In the present study, chronic administration of sunitinib and imatinib had no obvious adverse effects 
on cardiac function and haemodynamics.  Larger group sizes may have increased the chance of 
finding rare cardiotoxic effects, but the guinea pigs used here were healthy with no co-morbidities 
which may predispose to such effects.  Another likely explanation for the absence of effects on 
cardiac function is related to the duration of treatment which is far short of the weeks/months of 
treatment given to patients.  Other in vivo animal studies investigating cardiotoxicity have been 
performed over longer durations with periods of up to 6 weeks for imatinib (Kerkela et al., 2006, 
Wolf et al., 2010) and up to 5 weeks for sunitinib (Kerkela et al., 2009); however, it is of interest 
that in the later study, sunitinib had no effects on cardiac function in the mouse and caused only an 
apparent loss of cardiomyocytes.  In the current study the effects of imatinib, and sunitinib in 
particular, on CaMKII expression and activity were highly significant over 6 days of treatment. 
Despite CaMKII being highlighted in reports reviewing drug-induced cardiotoxicity (Zhou et al., 
2010; Stumman et al., 2009), no previous studies have investigated the effects of imatinib or 
sunitinib on cardiac contractility and CaMKII expression and/or activity.  However, interestingly a 
recent study examining the effects of imatinib on rat neonatal cardiomyocytes has reported 
significant activation of CaMKII activity in response to the anti-cancer drug (Barr et al., 2014). 
Clinically relevant doses of 2PM and 5PM imatinib were used and, in response to both 
concentrations, there was significant elevation of Thr17 phosphorylation of phospholamban and Ser 
2814 phosphorylation of the ryanodine receptor ± both selective substrates for CaMKII. This 
resulted in enhanced sarcoplasmic reticulum function as well as activation of NFAT (nuclear factor 
of activated T cells) signalling. This imatinib-dependent activation of Ca2+-handling resulted in 
pathological hypertrophy and necrotic cell death.  These results are particularly pertinent to the 
current study where along with measurement of CaMKII activity via selective incorporation of 
phosphate into a specific peptide substrate we also show evidence for increased pSer2815-RyR 
following chronic imatinib and sunitinib treatment.     
 
In the current study echocardiography assessment showed significant decreases in FS following 
chronic isoprenaline treatment; however, there was no increase in heart:body weight ratio and no 
histopathological effects suggesting that chronic E-adrenoceptor activation had not yet induced 
heart failure.  The decrease in FS was associated with left ventricular (LV) dilatation indicated by 
the significant increase in both LV end-diastolic and end-systolic diameter and also the increase in 
LVEDP.  Decreased contractile performance and increased CaMKII expression and activity are 
indicative of compromised cardiac function which can ultimately lead to heart failure (Anderson et 
al., 2007).  Isoprenaline has been administered chronically in several studies in mice (Kudej et al., 
1997; Friddle et al., 2000) and rat (Kitagawa et al, 1997, Takeshita et al., 2008), but less commonly 
in guinea pig (Maisel et al., 1987).  In all of these studies, chronic isoprenaline administration 
caused cardiac hypertrophy. CaMKII expression and activity are known to be increased following 
FKURQLFȕ-adrenoceptor stimulation and in hypertrophy and heart failure (Zhang et al., 2003).  Taken 
together this evidence supports the effects of chronic isoprenaline treatment observed in the current 
study.   
 
A decrease in fractional shortening and LVdP/dtmax was observed following administration of 
verapamil.  It was anticipated that chronic verapamil treatment would decrease contractile 
performance, given the negative inotropic effects of this drug.  This has been shown previously in 
rabbits chronically treated with verapamil (2 mg kg-1 day-1, 28 days) where a significantly lower 
force of contraction and a depressed contractile response to epinephrine in papillary muscles 
isolated from verapamil- treated animals was observed (Bosnjak et al., 1991).  By blocking Ca2+ 
entry into cardiomyocytes, theoretically, verapamil should result in a decrease in CaMKII activity 
and this was apparent following acute verapamil treatment.  However, chronic verapamil 
DGPLQLVWUDWLRQFDXVHG&D0.,,įH[SUHVVLRQDQG&D0.,,DFWLYLW\WRLQFUHDVH$OWKRXJKWKLVZDV
initially unexpected, similar effects of chronic verapamil treatment have been reported elsewhere in 
the rat (Zhou, 2010).  Chronic verapamil treatment (15 mg kg-1 day-1) caused several biochemical 
and functional changes to Ca2+ handling proteins, resulting in altered cardiac function.  Of particular 
relevance to the findings here, were the observations of increased CaMKII expression and 
hyperphosphorylation of RyR.  Interestingly, these changes occurred in the absence of cardiac 
hypertrophy or fibrosis following chronic verapamil treatment (Zhou, 2010).  Although, plasma 
cardiac troponin I was significantly increased in the current study, perhaps indicating cardiac 
damage, histological analysis revealed no morphological abnormalities.  Thus, biochemical changes 
may result in adverse effects on cardiac function without evidence of structural deficits. 
 
Potential mechanisms involved in effects on CaMKII 
It seems unlikely that imatinib and sunitinib are directly targeting CaMKII as these drugs were 
designed as kinase inhibitors rather than kinase activators.  It is possible that these drugs affect 
other signalling molecules up- or downstream of CaMKII which VXEVHTXHQWO\LQFUHDVH&D0.,,į
expression and CaMKII activity.  A potential link lies in the fact that CaMKII can be activated in 
vitro and in vivo by reactive oxygen species (ROS) acting via oxidation of Met281/282 in the 
autoregulatory domain (Erickson et al., 2008).  Mitochondria are an important source of ROS 
within most mammalian cells, and this underlies oxidative damage in many disease states (Murphy, 
0LWRFKRQGULDOSHUWXUEDWLRQDQGWR[LFLW\KDYHEHHQLGHQWLILHGDVD³FRPPRQWKHPH´LQGUXJ-
induced cardiotoxicity (Force et al., 2011) and imatinib and sunitinib have been linked to 
mitochondrial injury and abnormalities in mice, rat and humans (Kerkela et al., 2006; Wolf et al., 
2010).  In addition, sunitinib increased the generation of ROS in vitro (Mellor et al., 2011; Zhuang 
et al., 2011).  More recently, CaMKII activity has been identified as having a central role in the 
mitochondrial Ca2+ entry that precedes myocardial dysfunction and cell death (Joiner et al., 2012).  
Taken together these findings suggest CaMKII can be activated by oxidation resulting from ROS, in 
conjunction with cross-talk and potential feedback to the mitochondria. 
It is interesting to note that in vitro studies in rat neonatal cardiac myocytes suggest CaMKII 
inhibition can at least partly reverse the cardiotoxic effects of imatinib (Barr et al., 2014). Myocytes 
treated with AIP or infected with a virus containing a dn-CaMKII showed less imatinib-induced 
hypertrophic remodelling. In addition, imatinib-induced nuclear translocation of NFAT was blocked 
by the calcineurin inhibitor FK506, the CaMKII inhibitor AIP and by the L-type Ca2+ channel 
blocker Nifedipine. The authors suggest that imatinib increases the pool of cellular Ca2+available 
for activation of CaMKII and calcineurin-NFAT nuclear translocation which ultimately results in 
pathological hypertrophy. 
 
In the present study, we aimed to achieve clinically relevant concentrations of the test drugs in the 
chronic dosing protocol.  In general, this was achieved, with a mean total plasma concentration of 
1.36 PM and 0.01 PM achieved in the chronic phase for imatinib and sunitinib, respectively, 
compared to clinically efficacious concentrations of 2 PM (980 ng/mL) and 0.06 PM (25 ng/mL), 
respectively (Kitagawa et al., 2013). It is worth noting that the concentration of imatinib achieved in 
our chronic dosing is in line with the concentration (2PM) used in vitro (Barr et al., 2014) where 
significant CaMKII activation was observed. The concentration of verapamil achieved was also in 
the clinical range (0.16 PM vs 0.23 PM (105 ng.mL) (Freedman et al., 1981).   
In conclusion, findings presented here show for the first time that sunitinib and imatinib treatments 
affect CaMKII in the heart with chronic treatments leading to significantly increased CaMKII 
expression and activity. Given the strong link between chronic CaMKII elevation and 
cardiovascular dysfunction, this may be a mechanism by which sunitinib and imatinib exert at least 
part of their cardiotoxic side-effects. Further investigation is required to verify the mechanism of 
action of these kinase inhibitors upon CaMKII. 
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Table 1.  Haemodynamic measurements following chronic drug administration.   
 LVdP/dtmax LVEDP Heart rate SBP DBP H:BW 
Ratio  
 (mmHg s-1) (mmHg) (beats min-
1) 
(mmHg) (mmHg) (x1000) 
Vehicle 4809 ± 484 -3 ± 2 288 ± 20 57 ± 3 36 ± 2 3.31 ± 0.12 
Isoprenaline 4779 ± 169 4 ± 3* 300 ± 5 58 ± 2 37 ± 2 2.91 ± 0.04 
Verapamil 3176 ± 436* -6 ± 1 264 ± 14 42 ± 3* 24 ± 3* 3.25 ± 0.11 
Imatinib 4938 ± 574 -6 ± 1 318 ± 17 55 ± 3 28 ± 3 3.20 ± 0.11 
Sunitinib 4548 ± 156 -2 ± 1 283 ± 4 53 ± 3 29 ± 1 3.25 ± 0.25 
 
DBP, diastolic blood pressure; LVdP/dtmax, left ventricular dP/dtmax; LVEDP, left ventricular end 
diastolic pressure; SBP, systolic blood pressure; H:BW ratio, heart:body weight ratio (multiplied by 
1000).  Mean ± S.E.M; n=6.  SFRPSDUHGWRYHKLFOHJURXSRQHZD\$129$SOXV'XQQHWW¶V
test. 
Figure Legends 
Figure 1.  Left ventricular (LV) dP/dtmax is reduced following acute sunitinib administration. LV 
dP/dtmax responses (% change from baseline) following acute drug administration are shown for 
vehicle, isoprenaline, verapamil, and sunitinib.  The grey bars indicate increasing drug doses.  
Baseline values (mmHg s-1): isoprenaline 2610 ± 500, verapamil 3627 ± 355, sunitinib 1803 ± 163, 
vehicle 2948 ± 580.  Mean ± SEM; n=4. *p<0.05 compared to value within group at time 0 min, 
Kruskal-Wallis test. 
 
Figure 2. Heart rate and arterial blood pressure are decreased following acute sunitinib 
administration. Heart rate (A), systolic blood pressure (BP) (B), and diastolic (C) (% change from 
baseline) are shown following acute drug administration of vehicle, isoprenaline, verapamil, and 
sunitinib, respectively.  The grey bars indicate increasing drug doses.  Baseline values: Heart rate 
(beats min-1), isoprenaline 266 ± 6, verapamil 284 ± 9, sunitinib 238 ± 7, vehicle 267 ± 16; Systolic 
blood pressure (mmHg), isoprenaline 62 ± 7, verapamil 59 ± 1, sunitinib 56 ± 2, vehicle 57 ± 3.  
Diastolic blood pressure (mmHg), isoprenaline 39 ± 5, verapamil 33 ± 2, sunitinib 39 ± 2, vehicle 
33 ± 2.  Mean ± SEM; n=4. *p<0.05 compared to value within group at time 0 min, Kruskal-Wallis 
test. 
 
Figure 3. ProteLQH[SUHVVLRQRI&D0.,,į and CaMKII activity are not altered significantly 
following acute sunitinib administration. (A) Representative &D0.,,įimmunoblots are shown for 
each treatment from three separate samples (6 µg total protein) and pooled histogram data showing 
quDQWLILFDWLRQRI&D0.,,į FDOFXODWHGDV&D0.,,į*$3'+DQGQRUPDOLVHGWRDFRQWUROVDPSOH
included in each blot) is shown below in the accompanying histogram normalised to GAPDH.  (B) 
Histogram showing CaMKII activity in guinea pig left ventricular (LV) homogenate (10 µg) 
following acute in vivo drug administration.  For activity assays, data was normalised to the same 
control untreated sample used across assays for consistency. Histogram data is Mean ± SEM; 
Vehicle n=6, isoprenaline n=5, verapamil n=5, sunitinib n=4.  *p<0.05 compared to vehicle, 
Kruskal-Wallis test. (C) Histogram showing CaMKII activity determined in triplicate in guinea pig 
/9KRPRJHQDWHȝJHLWKHUUHFHLYLQJQRWUHDWPHQWFRQWUROSUHWUHDWHGZLWKDQGȝ0
autocamtide-2 related inhibitory peptide (AIP), without (w/o) autocamtide substrate or w/o Ca2+. 
 
Figure 4. Chronic administration of sunitinib and imatinib do not significantly alter left ventricular 
contractility. (A) Echocardiography was used to calculate % fractional shortening (FS). The left-
hand panel shows a two-dimensional short axis view of the left ventricle (LV); the right-hand panel 
shows an M-mode recording indicating the lumen of the left ventricle (LV), anterior wall (AW), 
posterior wall (PW), LV systolic diameter (LVSD) and LV diastolic diameter (LVDD). (B) LV 
diastolic diameter (LVDD), (C) LV systolic diameter (LVSD) and (D) Left ventricular (LV) 
fractional shortening (%FS) are shown for pre and post chronic drug administration.  Mean ± SEM; 
n = 6.  *p<0.05 compared to pre-drug value, paired t-test. 
 
Figure 5. Chronic administration of either sunitinib or imatinib causes a significant increase in 
&D0.,,įH[SUHVVLRQ5HSUHVHQWDWLYHsignals for CaMKIIG and GAPDH from three individual blots 
are shown for each treatment (6 µg total protein) as indicated.  Corresponding mean data for each 
treatment FDOFXODWHGDV&D0.,,į:GAPDH and normalised to a control sample included in each 
blot) is shown below in the accompanying histogram.  Mean ± SEM; n = 6.  *p<0.05 compared to 
value vehicle group, Kruskal-Wallis test. 
 
Figure 6. CaMKII activity is significantly increased following chronic sunitinib and imatinib 
treatment. (A) Histogram showing mean CaMKII activity following chronic in vivo drug 
administration. (B) Immunoblots from three individual experiments showing pSer2815-RyR 
expression in representative LV homogenates (10 µg total protein) following chronic in vivo drug 
administration.  Corresponding mean data for each treatment (expressed as pSer2815RyR:GAPDH 
and normalised to a control sample included in each blot) is shown in the accompanying histogram.  
Mean ± SEM, n = 6.  *p<0.05 compared to vehicle group, Kruskal-Wallis test. 
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